Skip to content

State coverage

Arkansas Medicaid and GLP-1 coverage

State Medicaid · 5 documents cited

Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.

At a glance

Other diagnoses only
Medicaid, for obesity
Weight loss alone is excluded; Wegovy is covered for heart risk and liver disease, Zepbound for sleep apnea.
Appeal deadline
30 calendar days from the date of written notice, and the 30 days does not start counting until 5 days after that date source
Primary source
Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL)
Date read
September 2026

American GLP, Publisher · Who writes this site

Arkansas Medicaid says the same sentence in three separate criteria documents, almost word for word: it does not cover these drugs for weight loss alone. That sentence is not a throwaway — it is followed each time by a narrow, unrelated diagnosis that IS covered, which makes Arkansas one of the more specific conditional states on this site rather than a flat exclusion.

Wegovy has two such carve-outs, added over a year apart. An August 2024 prior-authorization memo covers it for reducing cardiovascular risk in a patient with established heart disease and a qualifying BMI — the same cardiovascular-outcomes indication Medicare and several other Medicaid programs use. A November 2025 memo adds a second, unrelated one: Wegovy for confirmed liver fibrosis from metabolic dysfunction-associated steatohepatitis (MASH), which has nothing to do with a scale reading and requires a liver biopsy or two separate non-invasive fibrosis tests to document.

Zepbound gets one carve-out, narrower still: obstructive sleep apnea, and only obstructive sleep apnea. The May 2025 criteria require a diagnosed AHI of 15 or more on a sleep study, a specialist prescriber, and — pointedly — six months of documented, unsuccessful CPAP compliance before the drug can be added rather than substituted for the CPAP machine.

The state's Preferred Drug List reflects the same split: its "Antidiabetic Agents – GLP-1 Receptor Agonists" class, revised July 1, 2026, lists Trulicity and Victoza as preferred and Mounjaro, Ozempic, Rybelsus and Xultophy as non-preferred — all diabetes brands. Wegovy and Zepbound do not appear on the PDL itself; they are handled entirely through the manual-review criteria quoted below, outside the preferred/non-preferred structure.

What we could verify for Arkansas

The state's diabetes GLP-1 class on the PDL never mentions weight loss and never lists Wegovy or Zepbound: "ANTIDIABETIC AGENTS – GLP-1 RECEPTOR AGONISTS... PREFERRED AGENTS: TRULICITY (dulaglutide)*, VICTOZA (liraglutide)* – BRAND ONLY. NON-PREFERRED AGENTS: exenatide (generic for BYETTA), liraglutide (generic for VICTOZA), MOUNJARO (tirzepatide), OZEMPIC (semaglutide), RYBELSUS (semaglutide), SOLIQUA (lixisenatide/insulin glargine), XULTOPHY (insulin degludec/liraglutide)."

Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL), effective July 2026 · source

Wegovy's first carve-out is cardiovascular, not weight-related, and says so up front: "NOTE: Arkansas Medicaid does not currently cover medications solely for the use of weight loss. PA requests for this medication must demonstrate that the patient has established cardiovascular disease and at risk for a major cardiovascular event." Approval requires a history of heart attack, stroke, stent, bypass or symptomatic peripheral arterial disease, plus a BMI of 27 or higher, and excludes anyone "[r]equested for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, July 17, 2024 meeting), effective August 2024 · source

Zepbound's only covered use is sleep apnea, and the memo repeats the same disclaimer before laying out the criteria: "Arkansas Medicaid does not cover medications solely for weight loss. The criteria listed below pertain to the obstructive sleep apnea indication only." It requires "moderate to severe obstructive sleep apnea (OSA) defined as apnea-hypopnea index (AHI) ≥15... based on polysomnography," a specialist prescriber, and denies anyone who "[h]as not been on a weight management program for at least 6 months" or is "[r]equested for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, April 16, 2025 meeting), effective May 2025 · source

A third, later memo adds a liver-disease carve-out for Wegovy specific to advanced fibrosis, again ruling out a plain weight-loss request: the beneficiary "must be diagnosed with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis," documented by biopsy or two separate fibrosis tests, prescribed with a liver specialist, and "[p]rior authorization request should not be for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, October 15, 2025 meeting), effective November 2025 · source

Arkansas beneficiaries get 30 days to appeal, and the manual is explicit that the clock does not start on the notice date itself: "the beneficiary may appeal. The appeal request must be in writing and submitted to the Department of Human Services, Appeals and Hearings Section... The appeal request must be received by the Appeals and Hearings Section no later than thirty (30) days from the date of written notice. The thirty (30) days begins to run five (5) days after the date of written notice."

Arkansas Department of Human Services, Medicaid Provider Manual, Section 191.004 (Administrative Appeals), effective June 2025 · source

Arkansas is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Arkansas Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Arkansas with the rest in the coverage matrix.

If you work for the State of Arkansas

State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: ARBenefits (Arkansas State Employees plan, Employee Benefits Division). Its pharmacy benefit runs through Navitus Health Solutions.

Weight loss drugs excluded; Ozempic for diabetes, MASH

ARBenefits doesn't cover weight loss medications, and its September 2026 drug list marks Wegovy, Zepbound, Saxenda and Foundayo as EXC. Ozempic and Mounjaro stay on tier 2, restricted to type 2 diabetes or MASH.

Under obesity coverage: "Weight loss medications are not a covered benefit." The plan covers "Bariatric Surgery as a treatment for Morbid Obesity" for members who meet listed conditions, including five years of continuous state or public school employment.

Arkansas Department of Shared Administrative Services, Employee Benefits Division, ARBenefits Summary Plan Document for Arkansas State Employees and Arkansas Public School Employees (revision 12-19-2025), effective January 2026 · source

"EBD has a contract with Navitus Health Solutions, LLC, who serves as the PBM (Pharmacy Benefit Manager) for the Plan."

Arkansas Department of Shared Administrative Services, Employee Benefits Division, ARBenefits Summary Plan Document for Arkansas State Employees and Arkansas Public School Employees (revision 12-19-2025), effective January 2026 · source

Under the heading "ANTI-OBESITY AGENTS" the list marks Wegovy, Zepbound, Saxenda and Foundayo with the code EXC in place of a tier number.

Arkansas Employee Benefits Division / Navitus, State of Arkansas Formulary, Alphabetical Index (last updated 9/1/2026), effective September 2026 · source

Ozempic sits on tier 2 as "OZEMPIC INJ (QL= 1 pack/28 days; Diagnosis Restricted- Type 2 Diabetes (E11) or MASH/NASH (K75.81))".

Arkansas Employee Benefits Division / Navitus, State of Arkansas Formulary, Alphabetical Index (last updated 9/1/2026), effective September 2026 · source

If the appeal fails, or you cannot wait

Arkansas Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.

Companies that pay this site a commission, what we found on each one's own site, and a link to check availability
CompanyWhat we found on its own site
PartnerHumeCare+Check availabilityA self-pay membership with no price shown before checkout, renewing automatically. The home page promises your money back if you don't lose 10 percent in six months; the terms limit that to 90 days, first-time users and no measurable loss.
PartnerEnhance MDCheck availabilityOffers compounded semaglutide and tirzepatide with provider consultations and follow-up. Compounded drugs are not FDA-approved; ask which pharmacy will dispense your prescription and what continuing care includes.
PartnerCoreAge RxCheck availabilityCompounded semaglutide advertised at $99 a month at every dose. The page our link opens has shown $149 instead, and a consultation fee can be added that may not be refundable.
PartnerOakCheck availabilityOne flat price at every dose, with shipping and supplies included free.
PartnerGala HealthCheck availabilityOne price at every dose. The advertised rate needs a yearly subscription.
PartnerDirect MedsCheck availabilityOne price at every dose from $147, with no monthly membership. The page states its discount two ways ($150 off in the banner, up to $200 off on the tiles), so check the total at checkout.

All 21 companies, with what we found on each →

Prices in those notes were read from each company's own site in September 2026, October 2026 and August 2026, and they change often. Check the current number before you buy.

Where this comes from

  1. Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL), effective July 2026 — Open the document
  2. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, July 17, 2024 meeting), effective August 2024 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo8-14-24.pdf
  3. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, April 16, 2025 meeting), effective May 2025 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo-5-14-25.pdf
  4. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, October 15, 2025 meeting), effective November 2025 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo11-12-25.pdf
  5. Arkansas Department of Human Services, Medicaid Provider Manual, Section 191.004 (Administrative Appeals), effective June 2025 — humanservices.arkansas.gov/wp-content/uploads/Final-Posting-Packet-Medic